We Are Crinetics
Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Read the Latest
April 12, 2021
Crinetics Announces Closing of Common Stock Offering
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has closed its previously announced underwritten follow-on offering of 4,562,044 shares of its common stock.
April 7, 2021
Crinetics Announces Pricing of Common Stock Offering
Paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 program in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated
Pipeline
We support patients, endocrinologists, and healthcare providers by finding better therapies for rare endocrine diseases and endocrine oncology such as:
- Acromegaly
- Neuroendocrine tumors (NETs)
- Congenital hyperinsulinism
- Cushing’s disease
- Congenital adrenal hyperplasia (CAH)
Our investigational drug for acromegaly is entering Phase 3. But that’s just at the forefront of the important work we’re doing to combat endocrine disease.
See the science >
Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|